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Abstract
Although combination antiretroviral therapy (ART) is highly effective in suppress-
ing viral load for people with HIV (PWH), many ART agents may exacerbate central
nervous system (CNS)-related adverse effects including depression. Therefore, under-
standing the effects of ART drugs on the CNS function, especially mental health, can
help clinicians personalize medicine with less adverse effects for PWH and prevent them
from discontinuing their ART to avoid undesirable health outcomes and increased likeli-
hood of HIV transmission. The emergence of electronic health records offers researchers
unprecedented access to HIV data including individuals’ mental health records, drug
prescriptions, and clinical information over time. However, modeling such data is very
challenging due to high-dimensionality of the drug combination space, the individ-
ual heterogeneity, and sparseness of the observed drug combinations. We develop a
1
ar
X
iv
:2
00
4.
05
48
7v
1 
 [s
tat
.M
E]
  1
1 A
pr
 20
20
Bayesian nonparametric approach to learn drug combination effect on mental health in
PWH adjusting for socio-demographic, behavioral, and clinical factors. The proposed
method is built upon the subset-tree kernel method that represents drug combinations
in a way that synthesizes known regimen structure into a single mathematical repre-
sentation. It also utilizes a distance-dependent Chinese restaurant process to cluster
heterogeneous population while taking into account individuals’ treatment histories.
We evaluate the proposed approach through simulation studies, and apply the method
to a dataset from the Women’s Interagency HIV Study, yielding interpretable and
promising results. Our method has clinical utility in guiding clinicians to prescribe
more informed and effective personalized treatment based on individuals’ treatment
histories and clinical characteristics.
KEY WORDS: Antiretroviral therapy, Distance-dependent Chinese restaurant pro-
cess, Longitudinal cohort study, Precision medicine, Subset-tree kernel.
1 Introduction
Early initiation and adherence to antiretroviral therapy (ART) regimens optimizes health
outcomes in people with HIV (PWH) and prevents further HIV transmission (Bangsberg
et al., 2001; de Olalla Garcia et al., 2002; Yun et al., 2005; Saag et al., 2018). However, viral
rebound is possible due to the high viral evolutionary dynamics and the occurrence of drug-
resistant mutations, ultimately resulting in treatment failure. ART agents fall into several
classes including nucleotide reverse transcriptase inhibitor (NRTI), non-nucleotide reverse
transcriptase inhibitor (NNRTI), protease inhibitor (PI), integrase inhibitor (INSTI), and
entry inhibitor (EI). Different drug classes target HIV via different mechanisms. While each
individual ART drug is susceptible to certain resistant mutations, a combination of drugs
from different drug classes can successfully suppress the virus. Therefore, modern ART
regimens typically combine three or more drugs of different classes.
Despite the remarkable success of effective ART reducing disease-related morbidity and
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mortality (Trickey et al., 2017), numerous observational studies have reported ART-related
adverse effects on central nervous system (CNS) function including depression, anxiety, sleep
disturbances, suicidal ideation, developmental disorders, and neurological toxicities (Rekha,
2018; Zash et al., 2018). For example, significant neuropsychiatric side effects such as night-
mares, hallucinations, and depression (Gaida et al., 2016), have been reported for EFV
(efavirenz), an NNRTI. Peripheral neuropathy has been reported for D4T (stavudine), an
NRTI, especially when used in combination with other NRTIs (Arenas-Pinto et al., 2016;
Saag et al., 2018). These side effects may result in ART discontinuation with downstream
consequences such as difficulties in work performance and functioning, HIV disease pro-
gression, and increased likelihood of HIV transmission (Fazeli et al., 2015; Watkins and
Treisman, 2015). Since ART is recommended for PWH indefinitely, it is critical to under-
stand and quantify drug effects, especially the drug combination effect, on CNS function to
facilitate the design and effectiveness of ART regimens.
In this paper, we focus on ART-related effect on depressive symptoms. Depression is one
of the leading mental health comorbidities in PWH, affecting from 20% to 60% of those with
the virus (Bengtson et al., 2016). Depression is associated with numerous adverse conse-
quences including poor ART adherence (Chattopadhyay et al., 2017), rapid disease progres-
sion (Ironson et al., 2017), and increased risk-taking behaviors (Brickman et al., 2017). The
high prevalence and the harmful effect of depression among PWH highlights the need for
effective clinical management and adequate treatment for depression. To date, few studies
are dedicated to investigating the effects of ART regimens on depression, many of which
present inconsistent findings. For instance, Pearson et al. (2009) and Mollan et al. (2014)
reported increased ART-related depression, whereas Okeke and Wagner (2013) and Jelsma
et al. (2005) reported the opposite. One possible explanation is that the effects of ART regi-
mens are heterogeneous and may be confounded by numerous factors such as socioeconomic
status, behavioral factors, and clinical performance. ART may alleviate depressive symp-
toms for some individuals through viral suppression and physical health improvement. For
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others, ART-related neurotoxicities may aggravate depression and lead to treatment failure.
Therefore, investigating the heterogeneous effects of ART on depression among PWH while
accounting for major confounders can help identify individual factors that drive depression
with ART exposure, thereby facilitating precision medicine for PWH.
Large-scale HIV datasets, such as the Women’s Interagency HIV Study (WIHS), provide
an opportunity and challenge to study the effects of ART regimens on depressive symptoms.
The WIHS is a prospective, observational, multicenter study which includes women with
HIV and women at-risk for HIV infection in the United States (Bacon et al., 2005). So-
ciodemographics, medication use, clinical diagnoses, and laboratory test results are collected
longitudinally with the goal of investigating the impact of HIV infection on multimorbidity.
For example, Figure 1(a, b) presents two individuals’ ART medication data versus their clinic
visits denoted by calendar dates. They were followed for different time periods with distinct
visit dates and drug uses. Their corresponding four depression scores were also recorded at
each visit measuring somatic symptoms, negative affect, lack of positive affect, and interper-
sonal symptoms. The depression scores were summarized from a self-report questionnaire
using the Center for Epidemiological Studies Depression Scale where a higher score reflects
worse symptoms (CES-D, Radloff 1977; Carleton et al. 2013), as shown in Figure 1(c, d).
The complexity of longitudinal observations, a heterogeneous population, and dynamic
and mixed ART assignments present four analytical and modeling challenges. The first chal-
lenge is high-dimensionality. With more than 20 ART drugs on the market, there are nearly
a half million possible drug combinations, making the estimation of drug combination effect
a high-dimensional problem. The second issue is unbalancedness. Some ART combinations
are frequent whereas others are rare. For example, D4T+LAM+NFV (two NRTIs + one PI)
was recorded 993 times in the WIHS, while a similar ART regimen D4T+LAM+ATZ was
only recorded 12 times. The third issue is sparseness. Only a tiny portion (hundreds of drug
combinations) of the high-dimensional ART regimen space were observed in the WIHS, while
the inference on the entire space is desired. Finally, there is the issue of non-stationarity.
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(c) Depression score for individual #1 (d) Depression score for individual #2
Figure 1: ART medication data and depression scores of two individuals versus their clinical
visits denoted by calendar dates.
Since PWH are given different ART regimens during the course of treatment, the effect of
the current regimen on depression is likely dependent on prior ART regimen use.
Statistical learning methods, such as logistic regression, tree-based models, and neural
networks have been used to study the effect of ART regimens on survivals and to predict vi-
rological responses (Altmann et al., 2007; Larder et al., 2007; Altmann et al., 2009; Caniglia
et al., 2017). However, the representations of ART regimens in these models were simplistic,
either using a binary variable to indicate whether an individual is on ART, or lumping ART
regimens together into a few coarse types. For example, Lundgren et al. (2002) dichotomizes
ART regimens into those with or without a PI. Bogojeska et al. (2010) proposed to predict
binary virological responses to ART regimens by fitting a separate logistic regression model
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for each regimen and borrowing information from similar regimens. The similarity between
regimens was defined by a linear additive function. Although computationally efficient, the
linear approach treats drugs as exchangeable and does not account for drug classes. More-
over, it cannot be easily extended for modeling ordinal or continuous outcomes, adjusting
for covariates, and considering treatment histories in a longitudinal setup.
To address the aforementioned challenges, we develop a novel Bayesian nonparametric
model using and extending subset-tree kernels (Collins and Duffy, 2002) and the distance-
dependent Chinese restaurant process (Blei and Frazier, 2011; Dahl et al., 2017) to es-
timate the effects of ART regimens on depressive symptoms after adjusting for relevant
socio-demographic, behavioral, and clinical factors. The subset-tree kernel method repre-
sents drug combinations in a way that synthesizes known regimen structure and the cor-
responding drugs into a single mathematical representation to induce an appropriate sim-
ilarity among different ART regimens. This formulation enables us to efficiently borrow
information across ART regimens and develop inferences and predictions on unobserved
ART regimens. Furthermore, we extend the subset-tree kernel among ART regimens to
sequences of ART regimens in a longitudinal setup, and use the distance-dependent Chi-
nese restaurant process as a prior to capture heterogeneity among individuals by considering
individuals’ treatment histories. The R code implementing our model can be found at
https://drive.google.com/open?id=1FB8o0cHx0lVq-PdEGZciVoknB8nCUXCI.
The rest of the paper proceeds as follows. In Section 2, we present the proposed Bayesian
nonparametric model along with the posterior inference. We evaluate the performance of
the proposed approach through simulation studies and sensitivity analyses in Section 3. In
Section 4, we apply the proposed model to a large-scale HIV clinical dataset to study the
effects of ART regimens on depressive symptoms. Finally, we conclude with a discussion in
Section 5.
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2 Model and Inference
2.1 Probability Model
Denote Yijq to be the score of depression item q for individual i at visit j, where i = 1, . . . , n,
j = 1, . . . , Ji, and q = 1, . . . , Q. Let Zij denote the ART regimen used by individual i
at visit j. For example, Zij = D4T+LAM+NFV if individual i takes a combination of
drugs D4T, LAM, and NFV at visit j. Let Xij be an S-dimensional vector including an
intercept, time-invariant covariates (e.g., race), and time-varying covariates (e.g., BMI, CD4
count) for individual i at visit j. We construct a sampling model for the depression score
Yij = (Yij1, . . . , YijQ)
T as follows,
Yij = βiXij + h(Zij) + ωij + εij, (2.1)
where βi is a Q×S dimensional matrix, h(·) is a Q-dimensional vector-valued function, ωij is
a Q-dimensional vector following a multivariate normal distribution N (0, σ2εΣω) that models
the dependency among different depression items, and εij ∼ N (0, σ2εIQ) is an independent
normal error. For identifiability, we assume Σω to be a correlation matrix. The first term
βiXij in (2.1) captures the dependence of the outcome Yij on the covariate Xij. The second
term h(Zij) is the key component of our model characterizing the combination effect of ART
regimen Zij, the details of which are given below.
Combination effect h(·). We construct h(·) with two desired properties: 1) sharing-of-
information - encouraging similar effects for similar ART regimens; and 2) parsimony -
reducing the high dimensional ART regimen space to a manageable size. Specifically, we
first pick a number D of representative ART regimens, denoted by z1, . . . , zD, which are
similar to the notion of knots in splines. Then we model the combination effect of ART
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regimen Zij using a kernel smoother,
h(Zij) =
∑D
d=1 κ(Zij, zd)γid∑D
d=1 κ(Zij, zd)
, (2.2)
where γid’s are Q-dimensional vectors and the kernel weights are defined by an ART regimen
similarity function κ(Zij, zd). How to choose these representative regimens will be discussed
later in the simulation studies and applications. The concept of similarity between different
regimens has been introduced in HIV studies. Bogojeska et al. (2010) proposed a linear kernel
method to compute the similarity between regimens based on the proportion of common
drugs that two regimens share, κ(zd, zd′) = (u
T
zd
uzd′ )/max(u
T
zd
1, uTzd′1), where uzd is a binary
vector indicating the drugs comprising the regimen zd and 1 is a vector of 1’s. Although
conceptually simple, the linear kernel treats all ART drugs as exchangeable and does not
account for drug classes. For example, the regimen D4T (NRTI) + LAM (NRTI) + NFV
(PI) should be more similar to D4T + LAM + ATZ (PI) than D4T + LAM + EFV (NNRTI)
since NFV and ATZ belong to the same drug class PI whereas EFV belongs to another class
NNRTI. However, the linear kernel approach gives rise to the same similarity score for these
two pairs.
We propose to use a subset-tree (ST) kernel method, which was originally developed in
natural language processing to represent sentence structure (Collins and Duffy, 2002). We
represent each ART regimen as a rooted tree which encodes the knowledge about the regimen
structure such as drug classes and the number of distinct drug classes under each regimen.
Figure 2 illustrates this idea using three regimens (A, B, C) as an example. Regimen A
contains D4T (NRTI) + LAM (NRTI) + EFV (NNRTI); regimen B contains D4T (NRTI)
+ LAM (NRTI) + IDV (PI); and regimen C contains FTC (NRTI) + TDF (NRTI) + ATZ
(PI) + RTV (PI). The linear kernel used in Bogojeska et al. (2010) would assign 0 similarity
score to regimens A and C since they share no common drugs. But the ST kernel will be
able to capture the similarity on the drug class level (highlighted by the yellow boxes). In
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fact, ST kernel calculates the similarity score between regimens across all levels of the tree
representation. This feature will later be further exploited to compute the similarity between
(longitudinal) sequences of regimens of possibly different lengths.
(a) Regimen A (b) Regimen B
FTC
A B C
A 5.23 2.13 0.50
B 2.13 5.23 1.25
C 0.50 1.25 6.51
(c) Regimen C (d) Similarity score matrix
Figure 2: Tree representations for ART regimens with their similarity matrix.
The main idea of the ST kernel is to compute the number of common substructures
between two trees Ta and Tb. Let RT denote the set of nodes for any tree T and let ch(r)
denote the set of children nodes of the node r ∈ RT (i.e., nodes immediately below r). The
similarity score, κ(Ta, Tb) between two regimen trees Ta and Tb, is calculated by
κ(Ta, Tb) =
∑
ra∈RTa
∑
rb∈RTb
ρ(ra, rb), (2.3)
where ρ(ra, rb) is defined for each pair of nodes as follows. (i) If ra and rb are terminal nodes
(ch(ra) = ch(rb) = ∅), then ρ(ra, rb) = 0. (ii) If ra and rb have different sets of children
nodes (ch(ra) 6= ch(rb)), then ρ(ra, rb) = 0. (iii) If ra and rb have the same nonempty set
of children nodes, then ρ(ra, rb) = η
∏|ch(ra)|
s=1
{
1 + ρ(chsra , ch
s
rb
)
}
, where | · | is the cardinality
of a set and chsra is a child of ra for s = 1, . . . , |ch(ra)|. Here we include a hyperparameter
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η ∈ (0, 1], which is a decay factor to control the relative influence from nodes near the root
to alleviate the peakiness of the ST kernel when the depth of tree fragments is considerably
large (Beck et al., 2015). Figure 2(d) presents the similarity score matrix among A, B, and
C when η = 0.5. Note that the self-similarity of regimen C is higher than those of regimens
A or B because regimen C consists of more drugs and therefore has a higher similarity score
due to the additive definition.
To estimate γid’s in (2.2), another challenge arises from the potential high-dimensionality
and multicollinearity of the kernel weights calculated from the similarity function. Following
the idea from principal component regression (Kendall et al., 1965), we consider a principal
component analysis on the design matrix that consists of kernel weights. Specifically, let Hij
be a D-dimensional vector whose d-th element is the kernel weight κ(Zij, zd)/
∑D
d=1 κ(Zij, zd),
and let H = (HT11, . . . ,H
T
1J1
, . . . ,HTn1, . . . ,H
T
nJn
)T be the N × D design matrix (N =∑n
i=1 Ji) for the kernel regression in (2.2). We perform the principal component analysis
on H and retain the first D? principal components that explain at least 99.9% of the total
variance. The resulting N ×D? matrix is denoted by H˜ . Then the combination effect h(·)
can be approximated by γ?i H˜ij, where γ
?
i is the Q×D? matrix that needs to be estimated.
2.2 Priors
To capture heterogeneity among individuals and individual treatment histories, we use the
distance-dependent Chinese restaurant process (ddCRP, Blei and Frazier 2011; Dahl et al.
2017) to induce clustering of individuals depending on the similarity between their treatment
histories. Let θi = {βi,γ?i }. We assume that θi ∼ ddCRP(m0, s, G0) with a mass parameter
m0, a base measure G0, and a similarity function s(·, ·).
We give a brief introduction to the ddCRP below. Due to the discrete nature of ddCRP,
{θi}ni=1 are likely to have ties. Let {θ˜k}rnk=1 denote the rn unique values of {θi}ni=1 where
θ˜k = {β˜k, γ˜?k}. Let pin = {S1, . . . , Sr} denote a partition of [n] = {1, 2, . . . , n} such that
∪rnk=1Sk = [n]. The ties among θi’s naturally give rise to a partition, i.e., θi = θ˜k if individual
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i belongs to cluster k, i ∈ Sk. Following Dahl et al. (2017), θi ∼ ddCRP(m0, s, G0) can be
written as
θi =
rn∑
k=1
θ˜kI(i ∈ Sk), θ˜k ∼ G0, pin ∼ p(pin). (2.4)
Denote σ = (σ1, . . . , σn) a permutation of [n], pi(σ1, . . . , σt−1) a partition of {σ1, . . . , σt−1},
and rt−1 the number of subsets in pi(σ1, . . . , σt−1), t ≤ n. The probability mass function of
the partition pin is defined as the product of increasing conditional probabilities (Dahl et al.,
2017),
p(pin | m0, s,σ) =
n∏
t=1
pt(m0, s, pi(σ1, . . . , σt−1)), (2.5)
where
pt(m0, s, pi(σ1, . . . , σt−1)) = Pr(σt ∈ S | m0, s, pi(σ1, . . . , σt−1))
=

t−1
m0+t−1
∑
σs∈S s(σt,σs)∑t−1
s=1 s(σt,σs)
, for S ∈ pi(σ1, . . . , σt−1)
m0
m0+t−1 , for S being a new subset,
(2.6)
and pt(m0, s, pi(σ1, . . . , σt−1)) = 1 for t = 1 by convention.
Similarity function s(·, ·). The similarity function s(·, ·) depends on individuals’ treat-
ment histories. Let Ti and Ti′ denote two sequences of treatment regimens for individuals
i and i′, respectively. The proposed ddCRP prior assumes that the prior probability that
they belong to the same cluster is proportional to the similarity score s(i, i′) = κ(Ti, Ti′).
Therefore, individuals with similar ART regimen histories are a priori more likely to be
clustered together. To measure the similarity between two regimen sequences, we extend the
ST kernel in (2.3) by combining multiple regimen trees into a single tree under the common
root “ART.” Figure 3 shows an example of the tree structure for one ART regimen sequence
with three distinct ART regimens. Then we apply the ST kernel in (2.3) to calculate the
similarity score between regimen sequences in the same fashion as before.
We complete the model by assigning hyperpriors. We use a conjugate gamma prior
11
1 2 3
(1) Stavudine (D4T) + Ritonavir (RTV) 
(2) Lamivudine (LAM) + Stavudine + Indinavir (IDV)
(3) Emtriva (FTC) + Tenofovir (TDF) + Nevirapine (NVP)
Reg1 Reg3Reg2
ART
D4T LAM D4T IDV NVPTDFFTCRTV
NRTI NRTI NNRTI
NRTI
PI PINRTI NRTI NRTI
PI NRTINRTI NNRTIPI
Figure 3: Tree representation (bottom) for a sequence of ART regimens (top).
Gamma(c0, d0) on m0, a conjugate inverse-gamma prior Inverse-Gamma(g1, g2) on σ
2
ε , and
a uniform distribution on the permutation, i.e., p(σ) = 1/n! for all σ, for ease of posterior
computation. In addition, we use a conjugate normal prior as the base measure θ˜k =
{β˜k, γ˜?k} ∼ G0. Specifically, let β˜kq and γ˜?kq be the q-th row of β˜k and γ˜?k , respectively.
We assume that β˜kq ∼ N (eq,Bq) and γ˜?kq ∼ N (fq,Λq) for k = 1, 2, . . . , rn, and q =
1, 2, . . . , Q, where eq ∼ N (0,E0), Bq ∼ Inverse-Wishart(b0,B−10 ), fq ∼ N (0,F0), and Λq ∼
Inverse-Wishart(λ0,Λ
−1
0 ). For the correlation matrix Σω, we assume that p(Σω) ∝ det(Σω)
following Lewandowski et al. (2009), where det(·) denotes the determinant of a matrix.
2.3 Posterior Inference
We carry out posterior inference with the Markov chain Monte Carlo (MCMC) algorithm.
The posterior sampling for ωij’s, Σω, and σ
2
ε is straightforward through standard Gibbs
sampler and Metropolis-Hastings sampler. To draw posterior samples for the parameters
related to the ddCRP prior, the key step is to compute the full conditional distribution of
the partition based on the probability mass function in (2.5) and (2.6). Suppose at the
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current state, the partition is pin = {S1, . . . , Srn} and let S−k , k = 1, 2, . . . , rn, denote these
subsets without individual i. Let pii→kn be the partition obtained by moving i from its current
subset to the subset S−k . Here we let k = 0 denote the index of a new empty subset S
−
0 ,
and let pii→0n denote the partition after moving i to a new subset. Then the full conditional
distribution for the allocation of individual i is given by,
p(i ∈ S−k | ·) ∝ p(pii→kn | m0, s,σ)
Ji∏
j=1
p(Yij | θ˜k),
for k = 0, 1, . . . , rn, where the new parameters θ˜0 are drawn from the base measure G0. Note
that p(pii→kn | m0, s,σ) is calculated by evaluating (2.5) and (2.6) at the partition pii→kn . More
details of the MCMC can be found in the Supplementary Material Section A.
3 Simulation Study
In this section, we conducted simulation studies to evaluate the performance of the proposed
model by comparing the posterior inference to the simulation truth. To demonstrate the
advantages of using the ddCRP prior for taking into account individuals’ heterogeneity and
treatment histories, and the ST kernel for inducing an appropriate ART regimen similarity,
we compared the proposed model to two alternative methods. The first alternative replaces
the ddCRP prior on θi = (β˜i, γ˜
?
i ) with independent conjugate multivariate normal priors
on β˜i’s and γ˜
?
i ’s that do not take into account individuals’ heterogeneity and treatment
histories, and replaces the ST kernel with a linear kernel (Bogojeska et al., 2010) based on the
proportion of common drugs that two regimens share, κ(zd, zd′) = (u
T
zd
uzd′ )/max(u
T
zd
1, uTzd′1),
where uzd is a binary vector indicating the drugs comprising the regimen zd and 1 is a vector
of 1’s. The linear kernel only considers the number of same drugs in each pair of regimens,
but ignores the drug class information. We call this method Normal+Linear. The second
alternative, called DP+Linear, replaces the ddCRP prior on θi with a Dirichlet process prior
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that does not account for individuals’ treatment histories and replaces the ST kernel with
the linear kernel as in the first alternative method. Furthermore, the robustness of the decay
factor η in the ST kernel was demonstrated by sensitivity analyses.
3.1 Simulation setup
Assume that there were n = 200 individuals with Q = 3 depression items and S = 3
covariates with one intercept, one time-invariant covariate, and one time-varying covariate,
i.e., Xij = (1, xi0, xij)
T, where xi0’s and xij’s were generated from independent standard
normal distributions, i = 1, . . . , n, j = 1, . . . , Ji. Individuals’ treatment histories were
randomly sampled from the WIHS dataset without replacement, resulting in the number of
visits per individual to range from 2 to 38. We set the simulated true decay factor ηo = 0.5,
and then computed the similarity scores among individuals’ treatment histories. Based on
the similarity scores among different individuals, we randomly generated one realization
from the ddCRP prior, yielding the simulated true number of clusters to be ron = 3 and the
number of individuals in each clusters is 67, 61, and 72, respectively. Figure 4(a) presents the
simulated true clustering scheme. Conditional on the clustering memberships, we generated
the simulated true {β˜kq}r
o
n
k=1,
Q
q=1 from a standard multivariate normal distribution, the values
of which are shown in Supplementary Table S1.
We selected representative drug regimens z1, . . . , zD if a regimen zd has been used in more
than 10 visits among all the 200 individuals, yielding D = 56. We generated the simulated
true {γ˜kq}r
o
n
k=1,
Q
q=1 in the kernel regression from a standard multivariate normal distribution,
and computed the kernel weight matrix H by applying the ST kernel in (2.3) to individu-
als’ treatment regimens and the selected representative drug regimens. We performed the
principal component analysis on the design matrix H , and chose the first D? = 39 principal
components for H˜ that explains 99.9% variation of the original matrix. We set the non-
diagonal elements of the correlation matrix Σω to be (σ12, σ13, σ23) = (0.25, 0.5, 0.75), and
σ2ε = 1. Lastly, we generated the depression scores Yij from (2.1).
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(a) Simulated true clustering scheme (b) Posterior probabilities of individual co-clustering
Figure 4: Simulated true clustering scheme and posterior probabilities of individual co-
clustering averaged over 100 repeated simulations.
We applied the proposed model to the simulated dataset with 100 repeated simulations.
The hyperparameters were set to be c0 = 1, d0 = 1, g1 = 1, g2 = 1, E0 = 100IS, b0 = S + 1,
B−10 = 100IS, F0 = 100ID? , λ0 = D
? + 1, and Λ−10 = 100ID? . For each analysis, we ran
10,000 MCMC iterations with an initial burn-in of 5,000 iterations and a thinning factor of 10.
Convergence diagnostic assessed using R package coda, including autocorrelation plots and
trace plots (Figures S2 and S3 in the Supplementary Material) of the post-burn-in MCMC
samples for some randomly selected parameters, showed no issues of non-convergence.
3.2 Simulation results
We first report on the performance in terms of recovering the individual clustering. Our
model successfully identified rˆn = 3 as it only overestimated the true number of clusters
by 1 in 2.24% of the post-burn-in MCMC posterior samples among all the 100 repeated
simulations. We further calculated the posterior probabilities of individual co-clustering
based on the empirical proportions of individuals being clustered in the same cluster over
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the post-burn-in MCMC samples. The co-clustering probability matrix averaged over 100
repeated simulations is shown in Figure 4(b), indicating that the proposed method assigns
individuals to their simulated true clusters with high probabilities.
Next, we examine whether we can recover the drug combination effect h(·). We randomly
selected one simulated dataset from 100 repeated simulations, and plotted the histogram of
the true drug combination effects overlaid with the empirical density of the posterior expected
combination effects in Figure S4 of the Supplementary Material. As for individual-specific
drug combination effects across visits, Figure 5 compares the simulation truths and the
estimated combination effects for two randomly selected individuals in this dataset. Both
Figure S4 and Figure 5 show that our model can well recover the drug combination effects.
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Figure 5: Combination effects for two randomly selected individuals from one randomly
selected simulated dataset. The horizontal axis is the index of visit, and the vertical axis
is the combination effect. The black lines represent the simulated truths of combination
effects, the green lines represent the estimations under the Normal+Linear method, the blue
lines represent the estimations under the DP+Linear method, and the red lines represent
the estimations under the proposed method (ddCRP+ST). The shaded area represents the
posterior 95% credible bands under the proposed method.
For parameter estimation, Figure S6 in the Supplementary Material plots the 95% esti-
mated credible intervals (CI) for β˜kq’s using the same simulated dataset, where the triangles
represent the simulation truths. As shown in Figure S6, all the 95% CI are centered around
the simulated true values. As another metric of performance, we computed, for each simu-
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lated dataset, the mean squared error (MSE) taken as the averaged squared errors between
the post-burn-in MCMC posterior samples and the simulated truth. Table S5 in the Supple-
mentary Material summarizes the mean and standard deviation of MSE across 100 simulated
datasets for β˜kq’s. Both Table S5 and Figure S6 show that the proposed method performs
well in terms of estimating the parameter values.
In addition, we compared the proposed method to two alternatives: the Normal+Linear
and the DP+Linear methods. Figure 5 compares the estimated combination effects under
the proposed model to those under the two alternative methods. The proposed method
with the ddCRP prior and the ST kernel well recovered the ground truth, while both the
Normal+Linear and DP+Linear methods had larger bias in estimating the drug combination
effects.
Lastly, to explore the sensitivity of the posterior inference with respect to the decay
factor η, we conducted inference under several values of η = 0.1, 0.3, 0.5, 0.8, 1 for one
randomly selected simulated dataset. The decay factor η was originally introduced in natural
language processing to alleviate the peakiness of the ST kernel when the depth of the tree
fragments is considerably large, in which case self similarities are disproportionately larger
than similarities between two different trees. Therefore, the decay factor η ∈ (0, 1], which
down-weights the contribution of large tree fragments to the kernel exponentially with their
sizes, could have significant influence on the inference if the tree structure is deep. However,
this is not the case in our application with relatively shallow trees. Figure 6 compares
the parameter estimations under different values of η, showing that there is no significant
difference among all these experiments.
4 Application: WIHS Data Analysis
The Women’s Interagency HIV Study (WIHS) is a multisite, longitudinal cohort study of
women living with HIV and women at-risk for HIV in the United States (Barkan et al.,
17
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1998; Adimora et al., 2018). Full details of the study design and prospective data collec-
tion are described at https://statepi.jhsph.edu/wihs/wordpress. Participants provide
biological specimens, complete physical examinations, and undergo extensive assessment of
demographic, clinical, and behavioral data via interviews at each visit. Included in this
assessment was the Center for Epidemiological Studies Depression Scale (CES-D, Radloff
1977), which is a self-report assessment of depressive symptoms spanning somatic (e.g.,
sleep and appetite difficulties), negative affect (e.g., loneliness and sadness), lack of positive
affect (e.g., hopelessness), and interpersonal symptoms (e.g., people are unfriendly). For the
present analysis, we included all women from the Washington, D.C. site in the WIHS with
at least five visits and complete CES-D data, which yielded n = 259 individuals. We also
extracted the following sociodemographic, behavioral, and clinical risk factors for depressive
symptoms: age, race, smoking status, substance use (e.g., marijuana, cocaine, and heroin),
body mass index (BMI), hypertension, CD4 count, and viral load. We selected D = 87
representative ART regimens in (2.2) using the same criterion as in the simulation study.
In particular, these representative ART regimens are combinations of 24 ART agents in five
drug classes: NRTI, NNRTI, PI, INSTI, and EI.
We applied the proposed model to the WIHS dataset using the same hyperparameters
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as in the simulation study and set the decay factor to be η = 0.5. We performed the
principal component analysis on the kernel weight matrix based on these 87 representative
ART regimens, and selected the first D? = 45 principal components that explain 99.9%
variation of the original matrix. We used 5,000 post burn-in samples after 5,000 iterations
with a thinning factor of 10 for posterior inference. The proposed model identified three
clusters, with the number of women in each cluster being 132, 84, and 43 respectively. Table
S7 in the Supplementary Material summarizes the demographic, clinical, and behavioral
characteristics of women in the three clusters at their initial visits, and Table S8 reports the
frequency of the 24 ART agents and their corresponding drug classes used by women in the
three clusters, respectively.
Figure 7 summarizes the posterior means and the corresponding 95% credible intervals
of the estimated coefficients with respect to age, CD4 count, viral load, and substance use
on four depression items in each cluster. As seen in Figure 7, the effects of covariates on
depressive symptoms were distinct among the three clusters. Panel (a) shows that younger
people had higher depressive symptoms in cluster 2, but lower depressive symptoms in clus-
ters 1 and 3. Panels (b) and (c) indicate that higher CD4 and lower viral load are associated
with lower depressive symptoms. Panel (d) shows a positive relationship between substance
use and depressive symptoms. These findings are consistent with the literature (Berg et al.,
2007; Springer et al., 2009; Grov et al., 2010; Taniguchi et al., 2014).
Next, we report the effects of ART regimens, i.e., drug combinations, on depressive symp-
toms in each cluster. Figure 8 plots the association between ART regimens and depressive
symptoms with respect to the first two principal components in each cluster. To explore the
patterns and interpret the estimated drug combination effects, we further list the top five
positively and negatively related ART regimens for each principal component in terms of the
coefficients of the loading matrix in Table 1. As shown in Figure 8, the first principal compo-
nent was negatively associated with all the depressive symptoms in cluster 1 and 3, but had
little effects in cluster 2. In addition, the first principal component was positively associated
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Figure 7: Posterior means and 95% CIs for the estimated coefficients corresponding to age,
CD4 count, viral load, and substance use in the real data analysis. The dots represent the
posterior means and the colors indicate different depressive symptoms.
with ART regimens consisting of two NRTI drugs FTC + TDF, an NNRTI drug EFV, RPV
or NVP, and an additional INSTI drug RAL (Table 1), which indicates a beneficial or pro-
tective effect for these ART regimens on depressive symptoms. In fact, combining two NRTI
drugs as backbone with an additional NNRTI drug was recommended as one of the first-line
therapies (Gu¨nthard et al., 2014), and previous clinical studies also reported that RAL was
well-tolerated and provided desirable viral suppression when used with certain NRTIs such
as TDF (Grinsztejn et al., 2007; Markowitz et al., 2007). Conversely, negative relationships
were observed between the first principle component and ART regimens consisting of two
NRTI drugs AZT + LAM and a PI drug such as LPV, revealing worse depressive symp-
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toms for women using these drug combinations. Rabaud et al. (2005) reported that a large
proportion of individuals receiving AZT + LAM + LPV experienced serious adverse effects,
especially gastrointestinal side effects such as nausea and vomiting, leading to poor toler-
ability of this regimen and treatment discontinuation. Furthermore, the second principal
component was positively associated with depressive symptoms in clusters 1 and 3. ART
regimens consisting of two NRTI drugs AZT + LAM and an NNRTI drug such as EFV
were positively related to the second principal component, while regimens consisting of two
NRTI drugs FTC + TDF and two PI drugs such as ATZ + RTV were negatively related
to the second principal component. Therefore, a combination of AZT, LAM, and EFV was
estimated to have adverse effects on depressive symptoms whereas a combination of FTC,
TDF, ATZ and RTV was estimated to have beneficial effects. Indeed, Gallant et al. (2006)
reported more frequent adverse effects and treatment discontinuation when individuals were
on EFV combined with AZT and LAM instead of FTC and TDF. Conversely, adding PI
drugs ATZ and RTV to NRTI drugs FTC and TDF yields both significant antiviral efficacy
and safety (Soriano et al., 2011).
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Figure 8: Posterior means and 95% CIs for the estimated combination effects on four de-
pressive symptoms with respect to the first two principal components in the WIHS data
analysis. The dots represent the posterior means and the colors indicate different depressive
symptoms.
The U.S. Department of Health and Human Services provides general guidelines on ART
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ART Regimens Loading Coefficients
Principal Components #1
FTC + TDF + EFV 0.182
FTC + TDF + RPV 0.182
FTC + TDF + NVP 0.181
FTC + TDF + EFV + RAL 0.174
DDI + TDF + EFV 0.162
AZT + LAM + LPV -0.171
AZT + LAM + SQV -0.165
DDI + LAM + LPV -0.163
ABC + LAM + LPV -0.162
AZT + LAM + IDV -0.162
Principal Components #2
AZT + LAM + EFV 0.179
AZT + LAM + NVP 0.178
ABC + AZT + LAM + EFV 0.169
ABC + AZT + EFV 0.159
AZT + DDI + NVP 0.156
FTC + TDF + DRV + RTV -0.191
FTC + TDF + FPV + RTV -0.190
FTC + TDF + ATZ + RTV -0.189
DDI + TDF + ATZ + RTV -0.182
FTC + TDF + ATZ -0.175
Table 1: Top five positively and negatively related ART regimens for the first two principal
components in terms of the coefficients of the loading matrix.
treatments; however, these guidelines do not take into account individual heterogeneity and
treatment histories. To make clinical decisions tailored to each person (precision medicine),
understanding the individualized adverse effect of each possible drug combination will be one
of the key contributors. The proposed method can accurately predict individuals’ adverse
effects of ART based on their clinical profiles, which can help guide clinicians to prescribe
ART regimens. For illustration, we randomly selected an individual from the WIHS dataset
with seven visits in total, who started AZT (NRTI) at the first visit, added LAM (NRTI) at
the second visit, and used the drug combination AZT + LAM + SQV (PI) from her fourth
to sixth visits. Then we considered two hypothetical scenarios. In the first scenario, we
assumed that the individual kept using the similar NRTI + PI drug combination as before
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but only replaced the PI drug SQV with a different PI drug LPV. In the second scenario, this
individual was switched to a distinct NRTI + NNRTI drug combination FTC (NRTI) + TDF
(NRTI) + EFV (NNRTI). Figure 9 plots the posterior predictive depression scores for this
individual at the last visit based on the information from her previous six visits under the two
hypothetical scenarios. As shown in Figure 9(c), there were no significant differences between
using different PI drugs when combined with NRTI drugs AZT and LAM as the backbone
treatment. However, using NRTI drugs FTC and TDF as the backbone with NNRTI drug
EFV demonstrated superior performance on alleviating depressive symptoms. As a result,
we would recommend the clinician to select the ART regimen FTC + TDF + EFV instead
of AZT + LAM + LPV for this particular individual. This example demonstrates that
the proposed method has the potential to guide more informed and effective personalized
medicine in HIV clinical practice.
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Figure 9: Predictive depression scores for an individual in the WIHS dataset with two
different hypothetical scenarios of ART medication use. The dashed lines represent the
predictive 95% credible bands with respect to each depressive symptom.
To facilitate the implementation of the proposed method in the decision process of HIV
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clinicians, and for broad application in personalized medicine, we have created an interac-
tive web application to illustrate this example using R package shiny (Chang et al., 2019),
available at https://wjin.shinyapps.io/Rshiny/. The web user interface interactively
displays the predictive depression scores of an individual in response to the user’s choice of
the individual’s clinical characteristics and ART medication use. Figure S9 in the Supple-
mentary Material shows a screenshot of the web application.
5 Conclusion
To facilitate a precision medicine approach, we proposed a novel Bayesian nonparametric
approach to estimate the effects of ART regimens on depressive symptoms. The method is
built upon the ST kernel method that quantifies similarities among ART regimens and the
ddCRP that accounts for individuals’ heterogeneity in both treatment histories and clinical
characteristics. Through simulation studies and analysis of the WIHS dataset, we have
demonstrated that the proposed model can accurately estimate the drug combination effects
and yield meaningful and interpretable results.
There are several potential extensions. First, the current similarity score is parame-
terized by a hyperparameter η. We could impose a prior on η and estimate it from the
posterior inference. It will require us to develop more efficient posterior samplers because in
each iteration of MCMC the similarity matrix needs to be recalculated at the current value
of η. Second, the similarity between ART regimens may also depend on the individuals’
socio-demographic, behavioral, and clinical characteristics. We could extend the model to
account for these factors by modifying the parameter γid in (2.2) as a function of these
variables. Finally, combination therapies are needed for many complex diseases beyond HIV
such as cancer and chronic diseases. Each chronic condition requires long-term medication
use. The proposed method can be applied to such electronic health records datasets (Gill
et al., 2010) to examine the side effects of combination therapies, potentially yielding better
24
therapy management for the elderly population and which has the potential to reduce public
healthcare costs.
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Supplemental Materials for “A Bayesian Nonparametric
Approach for Inferring Drug Combination Effects on Mental
Health in People with HIV”
A: Details of MCMC
A1: Summary of Model
Yij | θi ∼ N
(
βiXij + h(Zij) + ωij, σ
2
εIQ
)
, i = 1, 2, . . . , n, j = 1, 2, . . . , Ji,
θi = (βi,γ
?
i ) ∼ ddCRP(m0, s, G0),
where h(Zij) =
∑D
d=1 κ(Zij ,zd)γid∑D
d=1 κ(Zij ,zd)
is the drug combination effect that will be estimated by
a principal component regression, the covariates of which are derived from the first D?
principal components of the kernel weight matrix. Let γ?i be the corresponded coefficients
for the principal component regression, and θ˜k = (β˜k, γ˜
?
k)’s be the rn unique values of θi
induced by ddCRP, where k = 1, 2, . . . , rn.
We complete the model by assuming m0 ∼ Gamma(c0, d0), σ2ε ∼ Inverse-Gamma(g1, g2),
β˜kq ∼ N (eq,Bq) and γ˜?kq ∼ N (fq,Λq) independently for k = 1, 2, . . . , rn, and q = 1, 2, . . . , Q,
where eq ∼ N (0,E0),Bq ∼ Inverse-Wishart(b0,B−10 ), fq ∼ N (0,F0), Λq ∼ Inverse-Wishart(λ0,Λ−10 ),
ωij ∼ N (0, σ2εΣω), and p(Σω) ∝ det(Σω).
A2: Posterior Computation
A2.1: Update pin, the partition induced by ddCRP
p(i ∈ S−k | ·) ∝ p(pii→kn | m0, s,σ)
Ji∏
j=1
p(Yij | θ˜k)
for i = 1, 2, . . . , n and k = 0, 1, . . . , rn, where θ˜0 is a new and independent draw from G0.
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A2.2: Update m0, the mass parameter of ddCRP
p(m0 | ·) ∝ p(m0)p(pin | m0, s,σ) ∝ p(m0) Γ(m0)
Γ(m0 + n)
mrn0 .
Following the idea of Escobar and West (1995), we assign a Gamma distribution prior on
m0 and introduce an auxiliary variable τ0 ∼ Beta(m0 + 1, n). Then a closed form full
conditional posterior will be available for the mass parameter m0, which is a mixture of
Gamma distributions, i.e.,
τ0 | m0, · ∼ Beta(m0 + 1, n)
m0 | τ0, · ∼ c0 + rn − 1
c0 + rn − 1 + n(d0 − log(τ0))Gamma(c0 + rn, d0 − log(τ0))
+
n(d0 − log(τ0))
c0 + rn − 1 + n(d0 − log(τ0))Gamma(c0 + rn − 1, d0 − log(τ0)).
A2.3: Update σ, the permutation of subjects
We use Metropolis–Hastings algorithm to update σ. We first propose a new permutation
σ∗ by shuffling some randomly chosen integers in the current permutation σ and leaving the
rest in their current positions. As a symmetric proposal distribution, the proposed new σ∗
is accepted with probability
min
{
p(pin | m0, s,σ∗)p(σ∗)
p(pin | m0, s,σ)p(σ) , 1
}
= min
{
p(pin | m0, s,σ∗)
p(pin | m0, s,σ) , 1
}
,
since we are assuming a uniform distribution prior on the permutation.
A2.4: Update {θ˜k = (β˜k, γ˜?k)}rnk=1, the cluster specific parameters
p(θ˜k | Yi : i ∈ Sk) ∝ p(θ˜k)
∏
i∈Sk
Ji∏
j=1
p(Yij | θ˜k) ∝ G0
∏
i∈Sk
Ji∏
j=1
N (Yij; β˜kXij + γ˜?kH˜ij + ωij, σ2εIQ).
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• Update β˜kq, k = 1, 2, . . . , rn, q = 1, 2, . . . , Q
p(β˜kq | ·) ∝ N (eq,Bq)
∏
i∈Sk
Ji∏
j=1
N (Yijq;XTij β˜kq + H˜Tij γ˜?kq + ωijq, σ2ε) ∝ N (µn,Vn),
where µn = Vn
(
1
σ2ε
∑
i∈Sk
∑Ji
j=1 Y˜ijqXij +B
−1
q eq
)
, V −1n =
1
σ2ε
∑
i∈Sk
∑Ji
j=1XijX
T
ij +
B−1q , and Y˜ijq = Yijq − H˜Tij γ˜?kq − ωijq if i ∈ Sk.
• Update γ˜?kq, k = 1, 2, . . . , rn, q = 1, 2, . . . , Q
p(γ˜?kq | ·) ∝ N (fq,Λq)
∏
i∈Sk
Ji∏
j=1
N (Yijq;XTij β˜kq + H˜Tij γ˜?kq + ωijq, σ2ε) ∝ N (µn,Vn),
where µn = Vn
(
1
σ2ε
∑
i∈Sk
∑Ji
j=1 Y˜ijqH˜ij + Λ
−1
q fq
)
, V −1n =
1
σ2ε
∑
i∈Sk
∑Ji
j=1 H˜ijH˜
T
ij +
Λ−1q , and Y˜ijq = Yijq −XTij β˜kq − ωijq if i ∈ Sk.
A2.5: Update {eq}Qq=1, {Bq}Qq=1, {fq}Qq=1, {Λq}Qq=1, the hyper-parameters
• Update eq, q = 1, 2, . . . , Q
p(eq | ·) ∝ N (e0,E0)
rn∏
k=1
N (β˜kq; eq,Bq) ∝ N (µn,Vn),
where µn = Vn
(
E−10 e0 +B
−1
q
∑rn
k=1 β˜kq
)
and V −1n = E
−1
0 + rnB
−1
q .
• Update Bq, q = 1, 2, . . . , Q
p(Bq | ·) ∝ Inverse-Wishart(b0,B−10 )
rn∏
k=1
N (β˜kq; eq,Bq) ∝ Inverse-Wishart(bn,B−1n ),
where bn = b0 + rn and Bn = B0 +
∑rn
k=1(β˜kq − eq)(β˜kq − eq)T .
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• Update fq, q = 1, 2, . . . , Q
p(fq | ·) ∝ N (f0,F0)
rn∏
k=1
N (γ˜?kq;fq,Λq) ∝ N (µn,Vn),
where µn = Vn
(
F−10 f0 + Λ
−1
q
∑rn
k=1 γ˜
?
kq
)
and V −1n = F
−1
0 + rnΛ
−1
q .
• Update Λq, q = 1, 2, . . . , Q
p(Λq | ·) ∝ Inverse-Wishart(λ0,Λ−10 )
rn∏
k=1
N (γ˜?kq;fq,Λq) ∝ Inverse-Wishart(λn,Λ−1n ),
where λn = λ0 + rn and Λn = Λ0 +
∑rn
k=1(γ˜
?
kq − fq)(γ˜?kq − fq)T .
A2.6: Update {ωij}ni=1,Jij=1, the normal correlation term
p(ωij | ·) ∝ N (0, σ2εΣω)N (Yij;βiXij + γ?i H˜ij + ωij, σ2εIQ) ∝ N (µn,Vn),
where µn = Vn
(
1
σ2ε
Y˜ij
)
, V −1n =
1
σ2ε
IQ +
1
σ2ε
Σ−1ω , and Y˜ij = Yij − βiXij − γ?i H˜ij.
A2.7: Update Σω, the correlation matrix
p(Σω | ·) ∝ det(Σω)
n∏
i=1
Ji∏
j=1
N (ωij; 0, σ2εΣω) .
Since there is no closed-form solution, we will update it by Metropolis-Hasting algorithm.
A2.8: Update σ2ε , the variance of i.i.d normal errors
p(σ2ε | ·) ∝ Inverse-Gamma(g1, g2)
n∏
i=1
Ji∏
j=1
Q∏
q=1
N (Yijq;XTij β˜iq + H˜Tij γ˜?iq + ωijq, σ2ε) ∝ Inverse-Gamma(g∗1, g∗2),
where g∗1 = g1 +
1
2
n∑
i=1
Ji∑
j=1
Q∑
q=1
1, and g∗2 = g2 +
1
2
n∑
i=1
Ji∑
j=1
Q∑
q=1
(Yijq −XTij β˜iq − H˜Tij γ˜?iq − ωijq)2.
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B: Supplementary Tables and Figures
Parameters Simulation Truths
β˜11 (0.4201738, -1.5065858, 0.4573016)
β˜12 (0.1002570, 0.3885576, -2.5187332)
β˜13 (0.8705657, -0.3111586, -0.5348084)
β˜21 (-1.2951632, -0.07094494, -0.7004121)
β˜22 (-0.8044954, 0.12646919, -0.3280640)
β˜23 (1.3418530, -0.98949773, -0.3472228)
β˜31 (0.4265138, -0.2214469, 0.1368007)
β˜32 (-0.3282160, -2.4289411, -0.5135745)
β˜33 (0.5458084, 1.7959664, 0.7342632)
Table S1: Simultion truths of the parameters {β˜kq}r
o
n
k=1,
Q
q=1.
37
0 5 10 15 20 25 30
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Lag
Au
to
co
rre
la
tio
n
Autocorrelation plot for  β1,1,1
0 5 10 15 20 25 30
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Lag
Au
to
co
rre
la
tio
n
Autocorrelation plot for  β1,2,2
0 5 10 15 20 25 30
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Lag
Au
to
co
rre
la
tio
n
Autocorrelation plot for  β1,3,3
0 5 10 15 20 25 30
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Lag
Au
to
co
rre
la
tio
n
Autocorrelation plot for  β2,1,1
0 5 10 15 20 25 30
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Lag
Au
to
co
rre
la
tio
n
Autocorrelation plot for  β2,2,2
0 5 10 15 20 25 30
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Lag
Au
to
co
rre
la
tio
n
Autocorrelation plot for  β2,3,3
0 5 10 15 20 25 30
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Lag
Au
to
co
rre
la
tio
n
Autocorrelation plot for  β3,1,1
0 5 10 15 20 25 30
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Lag
Au
to
co
rre
la
tio
n
Autocorrelation plot for  β3,2,2
0 5 10 15 20 25 30
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Lag
Au
to
co
rre
la
tio
n
Autocorrelation plot for  β3,3,3
Figure S2: Autocorrelation plots for randomly selected β˜kqs’s using the post-burn-in MCMC
samples of the simulation dataset, k = 1, . . . , ron, q = 1, . . . , Q, s = 1, . . . , S. The plots show
no signs of non-convergence of the chains.
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Figure S3: Trace plots for randomly selected β˜kqs’s using the post-burn-in MCMC samples
of the simulation dataset, k = 1, . . . , ron, q = 1, . . . , Q, s = 1, . . . , S, where the dashed red
lines denote the simulated truths. The plots show no signs of non-convergence of the chains.
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Figure S4: Histogram of the true combination effects, overlaid with the empirical density plot
of the posterior expected combination effects for one randomly selected simulated dataset in
the simulation study.
Parameters Mean of MSE Standard Deviation of MSE
β˜11 (5.865e-03, 5.200e-03, 5.788e-03) (7.327e-03, 3.973e-03, 4.057e-03)
β˜12 (5.282e-03, 5.991e-03, 6.080e-03) (3.893e-03, 4.723e-03, 4.131e-03)
β˜13 (6.200e-03, 5.040e-03, 6.234e-03) (1.196e-02, 4.096e-03, 4.204e-03)
β˜21 (1.127e-02, 5.459e-03, 7.090e-03) (9.199e-03, 3.930e-03, 5.213e-03)
β˜22 (1.165e-02, 5.450e-03, 7.238e-03) (9.476e-03, 3.069e-03, 6.012e-03)
β˜23 (1.052e-02, 6.386e-03, 6.545e-03) (7.392e-03, 4.893e-03, 4.385e-03)
β˜31 (7.978e-03, 5.433e-03, 6.070e-03) (6.181e-03, 4.939e-03, 4.510e-03)
β˜32 (5.966e-03, 5.525e-03, 6.416e-03) (3.620e-03, 4.622e-03, 5.382e-03)
β˜33 (6.657e-03, 5.137e-03, 5.586e-03) (5.232e-03, 3.908e-03, 3.403e-03)
Table S5: Mean and standard deviation of mean squared error (MSE) across 100 simulated
datasets for {β˜kq}r
o
n
k=1,
Q
q=1. Each entry within the parentheses corresponds to one cluster and
one depression item.
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Figure S6: 95% credible intervals of the estimated parameters {β˜kqs}r
o
n
k=1,
Q
q=1 ,
S
s=1 for one
randomly selected simulated dataset in the simulation study, where the triangles represent
the simulated true values.
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Overall Cluster
(n = 259) 1(n = 132) 2(n = 84) 3(n = 43)
Variables n(%) n(%) n(%) n(%)
Demographics
Age
<= 25 16(6) 8(6) 6(7) 2(5)
26− 35 95(37) 37(28) 43(51) 15(35)
36− 45 101(39) 60(45) 23(27) 18(42)
46− 55 42(16) 25(19) 11(13) 6(14)
> 55 5(2) 2(2) 1(1) 2(5)
Race
White 42(16) 18(14) 20(24) 4(9)
African-American 200(77) 106(80) 57(68) 37(86)
Others 17(7) 8(6) 7(8) 2(5)
Clinical Characteristics
Body Mass Index
< 18.5 4(2) 3(2) 1(1) 0(0)
18.5− 24.9 75(29) 39(30) 23(27) 13(30)
25.0− 29.9 89(34) 45(34) 32(38) 12(28)
≥ 30.0 91(35) 45(34) 28(33) 18(42)
CD4 Count
<= 250 69(27) 38(29) 17(20) 14(33)
251− 500 109(42) 58(44) 39(46) 12(28)
501− 1000 70(27) 32(24) 22(26) 16(37)
>= 1001 11(4) 4(3) 6(7) 1(2)
Viral Load
<= 500 136(53) 70(53) 45(54) 21(49)
501− 5000 41(16) 17(13) 16(19) 8(19)
5001− 50000 50(19) 29(22) 12(14) 9(21)
>= 50001 32(12) 16(12) 11(13) 5(12)
Hypertension
Yes 66(25) 36(27) 18(21) 12(28)
No 193(75) 96(73) 66(79) 31(72)
Behavioral Characteristics
Smoke Status
Yes 110(42) 51(39) 37(44) 22(51)
No 149(58) 81(61) 47(56) 21(49)
Substance Use
Yes 38(15) 20(15) 12(14) 6(14)
No 221(85) 112(85) 72(86) 37(86)
Table S7: Demographic, clinical and behavioral characteristics of individuals at the initial
visit in the overall sample and in the three clusters.
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Overall Cluster
(n = 259) 1(n = 132) 2(n = 84) 3(n = 43)
ART Drugs n(%) n(%) n(%) n(%)
NRTI
Abacavir (ABC) 109(42) 60(45) 29(35) 20(47)
Zidovudine (AZT) 166(64) 79(60) 59(70) 28(65)
Stavudine (D4T) 115(44) 57(43) 36(43) 22(51)
Zalcitabine (DDC) 25(10) 13(10) 10(12) 2(5)
Didanosine (DDI) 91(35) 44(33) 35(42) 12(28)
Emtricitabine (FTC) 192(74) 101(77) 60(71) 31(72)
Lamivudine (LAM) 213(82) 105(80) 70(83) 38(88)
Tenofovir Disoproxil Fumarate (TDF) 210(81) 110(83) 67(80) 33(77)
NNRTI
Efavirenz (EFV) 128(49) 58(44) 46(55) 24(56)
Etravirine (ETV) 20(8) 14(11) 1(1) 5(12)
Nevirapine (NVP) 64(25) 33(25) 25(30) 6(14)
Rilpivirine (RPV) 23(9) 13(10) 7(8) 3(7)
PI
Atazanavir (ATZ) 102(39) 50(38) 33(39) 19(44)
Darunavir (DRV) 52(20) 27(20) 11(13) 14(33)
Fosamprenavir (FPV) 22(8) 13(10) 6(7) 3(7)
Indinavir (IDV) 63(24) 29(22) 24(29) 10(23)
Lopinavir (LPV) 73(28) 37(28) 26(31) 10(23)
Nelfinavir (NFV) 75(29) 33(25) 28(33) 14(33)
Ritonavir (RTV) 135(52) 68(52) 41(49) 26(60)
Saquinavir (SQV) 32(12) 14(11) 11(13) 7(16)
INSTI
Dolutegravir (DGT) 35(14) 19(14) 10(12) 6(14)
Elvitegravir (ELV) 15(6) 10(8) 4(5) 1(2)
Raltegravir (RAL) 55(21) 35(27) 12(14) 8(19)
EI
Maraviroc (SLZ) 5(2) 3(2) 0(0) 2(5)
Table S8: ART drugs used by individuals in the overall sample and in the three clus-
ters, where NRTI denotes nucleoside reverse-transcriptase inhibitors, NNRTI denotes non-
nucleoside reverse-transcriptase inhibitor, PI denotes protease inhibitor, INSTI denotes in-
tegrase inhibitor, and EI denotes entry inhibitor.
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Figure S9: A screenshot of the R Shiny web application. The web user interface interactively
displays the predictive depression scores of an individual in response to the user’s choice of
the individual’s clinical characteristics and ART medication use.
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